Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome

Therapeutic Advances in Chronic Disease - Tập 11 - 2020
Yongpeng Ge1, Sizhao Li1, Shanshan Li1, Linrong He1, Xin Lü1, Guochun Wang2
1Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China
2Department of Rheumatology, China-Japan Friendship Hospital, Yinghua East Road, Chaoyang District, 100029, Beijing, China

Tóm tắt

Background: Anti-KS autoantibodies are rare myositis-specific autoantibodies that have been described to target asparaginyl-transfer RNA synthetase. Methods: Here, we review the published literature on critical issues concerning the detection of anti-KS antibodies and the clinical features associated with their presence. Results: Seven articles are reviewed, in all of which immunoprecipitation was employed for the detection of anti-KS antibodies. A total of 47 patients were included; the ratio of females to males was 1.9:1. In total, 46 (98%) of these patients had interstitial lung disease (ILD), which was the sole manifestation in half (50%) of them. Pulmonary pathology revealed 7 (27%) with usual interstitial pneumonia, and 16 (62%) with non-specific pneumonia. Arthritis was present in about one-quarter (26%) of patients, and the incidence of Raynaud’s phenomenon and mechanic’s hands was 19% and 32%, respectively. However, manifestations of myositis were rare (9%). In addition, three (11%) patients had malignant tumors. Most patients responded to glucocorticoid therapy. Conclusions: Identifying anti-KS in patients with ILD may be useful for treatment, but reliable practical detection is needed. Furthermore, clinicians need to be aware of the possible presence of anti-KS antibodies in patients with ILD, either isolated or in combination with myositis.

Từ khóa


Tài liệu tham khảo

Trallero-Araguás E, 2016, et al, 46, 225

10.2174/0929867322666150514094935

10.1097/BOR.0000000000000434

10.1016/j.autrev.2014.01.022

Hirakata M, 1999, et al, 162, 2315

Hirakata M, 2007, et al, 56, 1295

Okayasu K, 2009, et al, 48, 1301

Koreeda Y, 2010, et al, 49, 361

Hamaguchi Y, 2013, et al, 8

Schneider F, 2015, et al, 139, 122

Aiko N, 2020, et al, 58, 196

10.1016/S0014-5793(01)02340-7

Vulsteke JB, 2019, et al, 18, 658

Cavagna L, 2019, et al, 8, 2013

Debray MP, 2015, et al, 84, 516

Yamakawa H, 2018, et al, 96, 210

Yamasaki Y, 2016, et al, 26, 403

Thông tin
Thông tin xuất bản

Therapeutic Advances in Chronic Disease

Tập 11

Thông tin tác giả